Emerging drugs for the prevention of migraine.
Expert Opin Emerg Drugs
; 26(3): 271-280, 2021 09.
Article
en En
| MEDLINE
| ID: mdl-34263680
ABSTRACT
INTRODUCTION:
Migraine is a common and disabling neurological disorder. A greater understanding of the pathophysiological mechanisms underlying migraine has led to the availability of specific new drugs targeting calcitonin gene-related peptide (CGRP). The success of the CGRP inhibitors validates research efforts into migraine-specific therapies. AREAS COVERED There are additional promising therapeutic targets that will be covered in this paper, focusing on the pain phase. They include pituitary adenylate cyclase-activating polypeptide (PACAP), the orexinergic system, the nitric oxide signaling pathway specifically neuronal nitric oxide synthase inhibitors (nNOSi), and metabotropic glutamate receptor 5 (mGluR5). EXPERT OPINION Based on currently available research; the targets discussed in this paper are all on equal footing with each other in terms of their potential as effective novel migraine therapies. There is a need for more clinical trials to pinpoint which of these potential drug targets will be effective for migraine preventio.Palabras clave
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Preparaciones Farmacéuticas
/
Trastornos Migrañosos
Límite:
Humans
Idioma:
En
Revista:
Expert Opin Emerg Drugs
Asunto de la revista:
TERAPIA POR MEDICAMENTOS
Año:
2021
Tipo del documento:
Article
País de afiliación:
Reino Unido